title: [New options for the pharmacotherapy of Alzheimer's disease after the registration of memantine?].
authors.affiliation: Zentralinstitut für Seelische Gesundheit Mannheim, Universität Heidelberg. froelich@zi-mannheim.de
authors.forename: L
authors.initials: L
authors.lastname: Frölich
authors.forename: B
authors.initials: B
authors.lastname: Schmitt
authors.forename: P
authors.initials: P
authors.lastname: Calabrese
authors.forename: H
authors.initials: H
authors.lastname: Diener
authors.forename: H
authors.initials: H
authors.lastname: Förstl
authors.forename: H J
authors.initials: HJ
authors.lastname: Gertz
authors.forename: J F
authors.initials: JF
authors.lastname: Hallauer
authors.forename: H
authors.initials: H
authors.lastname: Hampel
authors.forename: R
authors.initials: R
authors.lastname: Ihl
authors.forename: K
authors.initials: K
authors.lastname: Rieke
authors.forename: M
authors.initials: M
authors.lastname: Riepe
authors.forename: T
authors.initials: T
authors.lastname: Supprian
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D008559:Memantine / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018697:Nootropic Agents / Q000627:therapeutic use*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000187:drug effects; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D002800:Cholinesterase Inhibitors; D015259:Dopamine Agents; D018696:Neuroprotective Agents; D018697:Nootropic Agents; D016194:Receptors, N-Methyl-D-Aspartate; D008559:Memantine